Clinical Trials

Genetic Immunity's DermaVir Patch is our candidate Therapeutic Vaccine designed for HIV-specific immune reconstitution. The Antiviral Mechanism of Action is based on inhibition of viral replication by cytotoxic killing of HIV-infected cells. Currently, there are no approved immune therapy or vaccine products on the market for HIV/AIDS.

Clinical Trials involving DermaVir Patch, 2009:


Location
(clinicaltrials.gov ID)
Title Status

GIHU004
Hungary
(NCT00712530)


To read Study Synopsis click here...
A Phase I Study to Evaluate the Tolerability and Safety of DermaVir Immune Therapy in HIV-infected Subject under Treatment with HAART Excellent safety, tolerability, and immunogenicity: DermaVir evoked long-lasting gag-specific T cells 6- to 18,000 fold above pre-treatment values in all nine patients, in dose dependent manner.

ACTG 5176
USA
(NCT00270205)


To read Study Synopsis click here...
A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of DermaVir Patch Immune Therapy in HIV-infected Subjects Currently Under Treatment with HAART 24 of the 24 patients enrolled, the trial is still blinded.

GIEU006
Germany
(NCT00711230)


To read Study Synopsis click here...
A Phase II, Randomized, Study to Evaluate the Safety, Tolerability, Immunogenicity and Antiviral Activity of DermaVir Patch Immune Therapy in HIV-1 Infected treatment-naïve Subjects 36 of the 36 patients are enrolled. Trial so far shows excellent safety and tolerability, still blinded for efficacy.

PHPC-02
Italy


To read Study Synopsis click here...
Antiretroviral sparing concept: a Phase II, randomized, single blind placebo controlled study to investigate the effect of DermaVir immunization on the quantity of HIV-specific T cells during HAART followed by analytical treatment interruption 16 of the 16 patients enrolled, the trial is still blinded.

IMPAACT-P1049
USA


A Phase I/II study of the safety, tolerability and immunogenecity of a topical therapeutic DNA denritic cell vaccine (DermaVir Patch) in children, adolescents and young adults with hiv-1 infection on highly active antiretroviral therapy (HAART). In preparation


  
 

 


Search 
Print this sheet... Send this sheet...
   Home | About Us | Technology | Products | Pipeline | Clinical Trials | Newsroom | Investors | Contacts | Site Map Last Update: May 12, 2009